Icon (NASDAQ:ICLR) Updates FY 2026 Earnings Guidance

Icon (NASDAQ:ICLR) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 10.000-11.000 for the period, compared to the consensus earnings per share estimate of 10.380. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $8.0 billion.

Icon Stock Performance

Icon stock opened at $172.08 on Thursday. The firm has a 50 day simple moving average of $144.41 and a 200-day simple moving average of $136.87. The stock has a market cap of $13.18 billion, a price-to-earnings ratio of 30.62, a price-to-earnings-growth ratio of 8.24 and a beta of 1.22. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.14 and a quick ratio of 1.14. Icon has a 1-year low of $66.57 and a 1-year high of $211.00.

Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Tuesday, June 23rd. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.07. The firm had revenue of $2.03 billion for the quarter, compared to analyst estimates of $1.98 billion. Icon had a net margin of 5.35% and a return on equity of 8.73%. Icon’s revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the firm earned $3.43 EPS. On average, analysts expect that Icon will post 9.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ICLR. Piper Sandler cut shares of Icon to a “neutral” rating in a report on Thursday, May 28th. Bank of America raised their price target on shares of Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a research report on Thursday, June 25th. Leerink Partners set a $145.00 price objective on Icon in a research report on Thursday, May 28th. Barclays increased their price objective on Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research note on Thursday, June 25th. Finally, TD Cowen boosted their target price on Icon from $164.00 to $197.00 and gave the stock a “buy” rating in a research note on Thursday, June 25th. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $173.19.

Institutional Trading of Icon

A number of institutional investors have recently bought and sold shares of the business. WINTON GROUP Ltd purchased a new position in shares of Icon in the 2nd quarter valued at about $254,000. Daiwa Securities Group Inc. boosted its holdings in Icon by 19.3% in the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock valued at $4,094,000 after purchasing an additional 4,546 shares in the last quarter. Frontier Capital Management Co. LLC grew its position in shares of Icon by 97.6% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock valued at $10,379,000 after buying an additional 35,253 shares during the last quarter. Peapack Gladstone Financial Corp acquired a new stake in Icon during the 2nd quarter worth $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Icon by 58.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 289 shares during the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.